腫瘍壊死因子（TNF）阻害薬の世界市場規模：薬剤タイプ別、用途別、流通チャネル別、地域別、範囲および予測

腫瘍壊死因子（TNF）阻害薬の市場規模と予測

腫瘍壊死因子（TNF）阻害薬の市場規模は、2024年に2,488億米ドルと評価され、2024年から2031年にかけて64.00%のCAGRで成長し、2031年には13兆196億5,000万米ドルに達すると予測されます。TNF阻害剤は、炎症性サイトカインであるTNF-aを抑制する薬剤であり、全身性の炎症と免疫学的反応に関与しています。TNF-aは、関節リウマチ、乾癬、クローン病、強直性脊椎炎などの自己免疫疾患や炎症性疾患の開発の主な要因です。これらの薬はTNF-aをブロックし、炎症を抑え、症状を緩和し、病気の進行を遅らせる。

腫瘍壊死因子（TNF）を阻害する薬剤は、様々な炎症性疾患や自己免疫疾患の治療を一変させました。これらの薬剤は、様々な慢性疾患の発症に関与する炎症性サイトカインであるTNFαを標的とし、中和することによって機能します。TNF阻害剤は主に関節リウマチの治療に用いられます。関節リウマチは慢性的な自己免疫疾患で、炎症と関節の変性を引き起こします。

腫瘍壊死因子（TNF）阻害薬の今後の使用は、現在進行中の調査により、現在の用途よりも幅広い疾患の治療への可能性が明らかになるにつれ、飛躍的に伸びると予想されます。TNF阻害剤は従来から、関節リウマチ、クローン病、乾癬などの自己免疫疾患の治療に使用されており、これらの疾患に関与する炎症性サイトカインであるTNFαを標的として中和します。

腫瘍壊死因子（TNF）阻害薬の世界市場力学

主な市場促進要因

自己免疫疾患の増加

関節リウマチ、クローン病、乾癬などの自己免疫疾患の有病率が上昇していることが、TNF阻害薬の需要を牽引しています。世界保健機関（WHO）によると、自己免疫疾患は世界的に増加傾向にあり、関節リウマチだけでも人口の1％を占めると推定されています。

バイオテクノロジーの進歩

最近のバイオテクノロジーの動向は、TNF阻害剤の開発と有効性を大幅に改善しました。製剤の改良とバイオシミラーのイントロダクションより、治療の選択肢が増え、TNF阻害薬がより安価に入手できるようになっています。例えば、バイオシミラーの開発により治療費が削減される一方、市場競争は激化し、TNF阻害薬市場の成長をもたらしています。

認識と診断の向上：

自己免疫疾患に対する理解の向上と早期発見は、TNF阻害剤に対するニーズの高まりに寄与しています。啓発キャンペーンや診断ツールの進歩に伴い、TNF阻害が有効な疾患と診断される人が増えています。米国リウマチ学会によれば、早期かつ正確な診断は慢性疾患のより良い管理につながり、TNF阻害剤のような効果的な薬剤の重要性を強調しています。

主な課題

感染リスク：

TNF阻害薬は免疫系を低下させ、感染症にかかりやすくします。これらの薬剤を使用している患者は、結核、真菌感染症、日和見病原体などの重篤な感染症にかかりやすくなります。治療開始前のモニタリングや潜在性結核のスクリーニングなどの予防措置は重要であるが、患者のケアや治療のアドヒアランスを複雑にします。

高コスト：

TNF阻害薬は最も高価な薬剤の一つです。これらの薬剤は高額であるため、患者、特に保険が完全に適用されない患者のアクセスが制限される可能性があります。また、このような経済的負担はヘルスケアシステムに負担をかけ、地域間や集団間で治療を受けられるかどうかの格差につながる可能性があります。

長期安全性に関する懸念

TNF阻害剤の長期安全性は依然として懸念の種です。TNF阻害剤の長期使用は、がんや自己免疫疾患のリスク上昇に関連しています。これらの危険性をさらに理解し、潜在的な悪影響を軽減する技術を特定するためには、長期的な調査が必要です。

主な動向

バイオシミラーの採用

注目すべき動向の一つは、TNF阻害剤のバイオシミラーの使用が増加していることです。バイオシミラーとは、先発品の生物学的製剤と実質的に同一のクローンで、より安価な選択肢を提供するものです。インフリキシマブやエタネルセプトのような主要なTNF阻害薬の特許が切れる中、バイオシミラーはコスト削減と同様の有効性・安全性プロファイルにより人気を集めています。

新たな適応症への拡大

TNF阻害剤は、これまで知られていなかった新たな用途で使用されています。この増加は、TNF阻害剤の治療用途の拡大を目指した継続的な調査と臨床研究を反映したものであり、新たな市場機会と様々な炎症性疾患に苦しむ患者に対するより良い治療選択肢につながる可能性があります。

新規TNF阻害剤の開発：

業界では、より優れた特性を持つ新規TNF阻害剤のイントロダクションが行われています。医薬品開発者は、有効性が向上し、副作用が少なく、患者のコンプライアンスが向上した次世代TNF阻害薬の開発に取り組んでいます。より特異的な作用機序を持ち、投与レジメンを強化した薬剤は革新的な例です。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 腫瘍壊死因子（TNF）阻害薬市場：薬剤タイプ別

• モノクローナル抗体（mAbs）
• 可溶性TNF受容体
• バイオシミラー

第5章 腫瘍壊死因子（TNF）阻害薬市場：用途別

• 関節リウマチ（RA）
• 乾癬および乾癬性関節炎（PsA）
• クローン病
• 強直性脊椎炎
• TNF阻害薬が使用されるその他の自己免疫疾患

第6章 腫瘍壊死因子（TNF）阻害薬市場：流通チャネル別

• 病院薬局
• 小売薬局・ドラッグストア
• オンライン薬局

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• Merck & Co.
• Samsung Bioepis
• Sanofi
• Boehringer Ingelheim

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Tumor Necrosis Factor TNF Inhibitor Drugs Market Size and Forecast

Tumor Necrosis Factor TNF Inhibitor Drugs Market size was valued at USD 248.8 Billion in 2024 and is projected to reach USD 13019.65 Billion by 2031, growing at a CAGR of 64.00% from 2024 to 2031. TNF inhibitors are medications that suppress the pro-inflammatory cytokine TNF-a which plays a role in systemic inflammation and immunological response. TNF-a is a key factor in the development of autoimmune and inflammatory disorders like rheumatoid arthritis, psoriasis, Crohn's disease, and ankylosing spondylitis. These medications block TNF-a, reducing inflammation, alleviating symptoms, and slowing the evolution of diseases.

Drugs that block tumor necrosis factor (TNF) have transformed the treatment of a variety of inflammatory and autoimmune disorders. These medications function by targeting and neutralizing TNF-alpha, a pro-inflammatory cytokine involved in the development of various chronic diseases. TNF inhibitors are primarily used to treat rheumatoid arthritis. RA is a chronic autoimmune illness that causes inflammation and joint degeneration.

The future use of Tumor Necrosis Factor (TNF) inhibitor medications is expected to grow dramatically as ongoing research reveals their potential in treating a larger spectrum of illnesses than their current uses. TNF inhibitors have traditionally been used to treat autoimmune disorders such as rheumatoid arthritis, Crohn's disease, and psoriasis by targeting and neutralizing TNF-alpha, a pro-inflammatory cytokine implicated in these conditions.

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Dynamics

The key market dynamics that are shaping the global tumor necrosis factor TNF inhibitor drugs market include:

Key Market Drivers:

Rising Incidence of Autoimmune Diseases

: The rising prevalence of autoimmune disorders such as rheumatoid arthritis, Crohn's disease, and psoriasis is driving demand for TNF inhibitor medications. According to the World Health Organization (WHO), autoimmune disorders are on the rise worldwide with rheumatoid arthritis alone accounting for an estimated 1% of the population.

Advancements in Biotechnology:

Recent advances in biotechnology have considerably improved the development and efficacy of TNF inhibitors. Improved medication formulations and the introduction of biosimilars are increasing therapy options and making TNF inhibitors more affordable. For example, the development of biosimilars has reduced treatment costs while increasing market competition resulting in growth in the TNF inhibitor market.

Increased Awareness and Diagnosis:

Better understanding and early detection of autoimmune disorders contribute to the increased need for TNF inhibitors. As awareness campaigns and diagnostic tools advance, more people are being diagnosed with illnesses that can benefit from TNF inhibition. According to the American College of Rheumatology, early and precise diagnosis leads to better management of chronic diseases emphasizing the importance of effective medications such as TNF inhibitors.

Key Challenges:

Infection Risk:

TNF inhibitors can depress the immune system making it more susceptible to infection. Patients using these drugs are more susceptible to serious infections such as tuberculosis, fungal infections, and opportunistic pathogens. Monitoring and preventive measures such as screening for latent tuberculosis before beginning treatment are critical but they also complicate patient care and therapy adherence.

High Cost:

TNF inhibitors are some of the most expensive drugs available. The high cost of these drugs may limit access for patients, particularly those without complete insurance coverage. This financial burden can also put a strain on healthcare systems leading to discrepancies in treatment availability between areas and populations.

Long-Term Safety Concerns

: TNF inhibitors' long-term safety remains a source of concern. Prolonged use of these medicines has been linked to an increased risk of cancer and autoimmune diseases. Long-term research is still required to further understand these dangers and identify techniques for reducing potential negative consequences.

Key Trends:

Biosimilar Adoption

: One notable trend is the increasing use of TNF inhibitor biosimilars. Biosimilars are virtually identical clones of branded biological medications that provide a more affordable option. With the patents for key TNF inhibitors such as infliximab and etanercept expiring, biosimilars have gained popularity due to their reduced cost and similar efficacy and safety profile.

Expansion into New Indications

: TNF inhibitors are being used in new ways that are not previously known. This increase reflects continuing research and clinical studies targeted at expanding the therapeutic applications of TNF inhibitors which could lead to new market opportunities and better treatment options for patients suffering from a variety of inflammatory disorders.

Development of Novel TNF Inhibitors:

The industry is seeing the introduction of novel TNF inhibitors with enhanced characteristics. Drug developers are working on next-generation TNF inhibitors with increased efficacy, fewer side effects, and greater patient compliance. Drugs with more specific modes of action and enhanced dosing regimens are examples of innovations.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Regional Analysis

Here is a more detailed regional analysis of the global tumor necrosis factor TNF inhibitor drugs market:

North America:

In North America, the tumor necrosis factor (TNF) inhibitor medicines market is primarily driven by the rising prevalence of autoimmune illnesses and increased investment in healthcare infrastructure. Autoimmune disorders like rheumatoid arthritis, Crohn's disease, and psoriasis are growing more widespread creating a greater need for effective therapies. According to the Centers for Disease Control and Prevention (CDC), roughly 54.4 million persons in the United States have arthritis including rheumatoid arthritis which considerably increases the need for TNF inhibitors.

Significant investment in healthcare infrastructure and research in North America fuels the growth of the TNF inhibitor market. The National Institutes of Health (NIH) announced a significant increase in funding for research on autoimmune illnesses and innovative therapeutic medicines including TNF inhibitors. In 2023, the NIH will devote nearly USD 1.4 Billion to autoimmune disease and inflammatory research underscoring the region's commitment to developing therapeutic choices and improving patient outcomes. This strong financial backing enables the discovery and availability of novel TNF inhibitors, hence promoting market growth.

Asia Pacific:

The tumor necrosis factor (TNF) inhibitor pharmaceuticals market is expanding rapidly in Asia Pacific owing to several causes. The rising prevalence of autoimmune illnesses in the region is the market's fastest-growing driver. According to the World Health Organization (WHO), autoimmune disorders such as rheumatoid arthritis and Crohn's disease are on the rise worldwide with a significant increase in Asia. This increased incidence immediately increases the demand for TNF inhibitors which are important in controlling these disorders since they target the inflammatory mechanisms that cause autoimmune diseases.

Another key driver for the TNF inhibitor market in the Asia Pacific is the expansion of healthcare infrastructure and improved access to innovative treatments. The region has experienced significant investment in healthcare infrastructure, particularly in growing nations such as India and China. This growth of healthcare infrastructure improves the availability and accessibility of TNF inhibitors allowing more patients to benefit from these sophisticated medicines. Furthermore, government initiatives and regulations aiming at improving healthcare access and affordability are driving the industry.

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market: Segmentation Analysis

The Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is segmented based on Drug Type, Application, Distribution Channel and Geography.

Tumor Necrosis Factor TNF Inhibitor Drugs Market, By Drug Type

• Monoclonal Antibodies
• Soluble TNF Receptor
• Biosimilars

Based on the Drug Type, the Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is bifurcated into Monoclonal Antibodies, Soluble TNF Receptor, and Biosimilars. Monoclonal antibodies are the dominant drug type in the global tumor necrosis factor (TNF) inhibitor drugs market. This dominance is due to their proven efficacy and established clinical track record in treating autoimmune diseases such as rheumatoid arthritis and Crohn's disease. Monoclonal antibodies like infliximab and adalimumab, specifically target TNF-alpha, a key driver of inflammation in these conditions offering significant therapeutic benefits and high patient response rates.

Tumor Necrosis Factor TNF Inhibitor Drugs Market, By Application

• Rheumatoid Arthritis (RA)
• Psoriasis and Psoriatic Arthritis (PsA)
• Crohn's Disease
• Ankylosing Spondylitis
• Other

Based on the Application, the Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is bifurcated into Rheumatoid Arthritis (RA), Psoriasis and Psoriatic Arthritis (PsA), Crohn's Disease, Ankylosing Spondylitis, Others. In the global tumor necrosis factor (TNF) inhibitor drugs market, Rheumatoid Arthritis (RA) is the dominant application. RA's dominance is due to its high prevalence and the severe impact it has on patients' quality of life. The Arthritis Foundation reports that RA affects approximately 1% of the global population leading to significant healthcare costs and treatment needs. TNF inhibitors are highly effective in managing RA symptoms and slowing disease progression making them a crucial part of RA treatment regimens.

Tumor Necrosis Factor TNF Inhibitor Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

Based on the Distribution Channel, the Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is bifurcated into Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies. Hospital pharmacies are the dominant distribution channel in the tumor necrosis factor (TNF) inhibitor drugs market. This dominance is primarily due to the specialized nature of TNF inhibitors which are often prescribed for complex autoimmune conditions like rheumatoid arthritis and Crohn's disease. Hospital pharmacies are equipped to handle the specific storage, handling, and administration requirements of these drugs ensuring proper management and monitoring of patient responses.

Tumor Necrosis Factor TNF Inhibitor Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is the dominant region in the global tumor necrosis factor (TNF) inhibitor drugs market. This dominance is primarily due to the region's advanced healthcare infrastructure, high prevalence of autoimmune diseases, and substantial investment in research and development. The U.S. and Canada have well-established healthcare systems and are early adopters of innovative treatments contributing to a high uptake of TNF inhibitors. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, approximately 1.5 million Americans suffer from rheumatoid arthritis highlighting the significant patient base for TNF inhibitors.

Key Players

• The "Global Tumor Necrosis Factor TNF Inhibitor Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Merck & Co., Samsung Bioepis, Sanofi, and Boehringer Ingelheim.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Key Developments

• In July 2022, Sandoz gained approval from the United States Food and Drug Administration (FDA) to examine its Supplemental Biologics License Application for a high-concentration formulation of 100 mg/mL (HCF) of its biosimilar Hyrimoz (adalimumab).
• In February 2022, MyMD Pharmaceuticals Inc. presented Phase 1 clinical study findings indicating that MYMD-1 reduces tumor necrosis factor-alpha (TNF-a), a key driver of aging, in the blood of healthy individuals.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, By Drug Type

• Monoclonal Antibodies (mAbs)
• Soluble TNF Receptor
• Biosimilars

5. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, By Application

• Rheumatoid Arthritis (RA)
• Psoriasis and Psoriatic Arthritis (PsA)
• Crohn's Disease
• Ankylosing Spondylitis
• Other autoimmune diseases where TNF inhibitors are used

6. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• Merck & Co.
• Samsung Bioepis
• Sanofi
• Boehringer Ingelheim

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References